Total Debt for Vertex Pharmaceuticals (VRTX)
According to Vertex Pharmaceuticals's latest reported financial statements, the company's latest reported total debt is $3.88B USD. Total debt is the sum of short-term and long-term interest-bearing borrowings on the balance sheet (notes, bonds, term loans, lease liabilities). Useful for leverage and refinancing risk — combine with cash on hand for net debt, and see total liabilities for the broader obligations picture.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingTotal DebtSwitch metric
Latest period
$3.88B
YoY change
+121.9%
5Y CAGR
+33.0%
Peak year (2025)
$3.88B
Latest annual
$3.88B
Total Debt history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
Total Debt history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
| Fiscal year | Period ended | Reported | Total Debt | YoY |
|---|---|---|---|---|
| 2025 | $3.88B | +121.9% | ||
| 2024 | $1.75B | +116.4% | ||
| 2023 | $808.40M | -10.1% | ||
| 2022 | $899.70M | -7.0% | ||
| 2021 | $967.40M | +3.8% | ||
| 2020 | $931.90M | +40.8% | ||
| 2019 | $661.66M | +12.8% | ||
| 2018 | $586.82M | -3.2% | ||
| 2017 | $606.43M | -27.9% | ||
| 2016 | $840.76M | +1.8% | ||
| 2015 | $826.24M | +0.2% | ||
| 2014 | $824.95M | +62.8% | ||
| 2013 | $506.58M | -27.3% | ||
| 2012 | $696.91M | +52.8% | ||
| 2011 | $455.95M | -15.1% | ||
| 2010 | $536.99M | +188.8% | ||
| 2009 | $185.91M | -35.3% | ||
| 2008 | $287.50M | +1337.7% | ||
| 2007 | $20.00M | -83.8% | ||
| 2006 | $123.75M | -31.3% | ||
| 2005 | $180.10M | -46.2% | ||
| 2004 | $335.00M | -7.9% | ||
| 2003 | $363.85M | +10.9% | ||
| 2002 | $328.14M | +0.2% | ||
| 2001 | $327.61M | -9.6% | ||
| 2000 | $362.34M | +5033.0% | ||
| 1999 | $7.06M | -28.0% | ||
| 1998 | $9.80M | +16.7% | ||
| 1997 | $8.40M | -1.2% | ||
| 1996 | $8.50M | +21.4% | ||
| 1995 | $7.00M | +9.4% | ||
| 1994 | $6.40M | +6.7% | ||
| 1993 | $6.00M | +17.6% | ||
| 1992 | $5.10M | +54.5% | ||
| 1991 | $3.30M | +3.1% | ||
| 1990 | $3.20M | — |
Total Debt values are taken from Vertex Pharmaceuticals's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Vertex Pharmaceuticals (VRTX) most recent annual total debt stands at $3.88B (2025) – surged 121.9% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Vertex Pharmaceuticals total debt compounded at +33.0% per year, with the latest reading among the more recent periods of the dataset.
The highest annual total debt of $3.88B was reported in 2025. The lowest in the available history was $3.20M in 1990.
Vertex Pharmaceuticals (VRTX) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $52.57B.
Vertex Pharmaceuticals Total Debt by Year
Vertex Pharmaceuticals Total Debt 2025: $3.88B
Vertex Pharmaceuticals total debt in 2025 was $3.88B, surged 121.9% from 2024. This figure represents the highest annual value in the available history.
Vertex Pharmaceuticals Total Debt 2024: $1.75B
Vertex Pharmaceuticals total debt in 2024 was $1.75B, surged 116.4% from 2023.
Vertex Pharmaceuticals Total Debt 2023: $808.40M
Vertex Pharmaceuticals total debt in 2023 was $808.40M, declined 10.1% below 2022.
Vertex Pharmaceuticals Total Debt 2022: $899.70M
Vertex Pharmaceuticals total debt in 2022 was $899.70M, declined 7.0% below 2021.
Vertex Pharmaceuticals Total Debt 2021: $967.40M
Vertex Pharmaceuticals total debt in 2021 was $967.40M.
See more financial history for Vertex Pharmaceuticals (VRTX).
Sector peers — Total Debt
Companies in the same sector as Vertex Pharmaceuticals, ranked by their latest total debt.
| Company | Total Debt | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $130.96B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $78.39B | Healthcare |
| AbbVie Inc. (ABBV) | $69.07B | Healthcare |
| Amgen Inc. (AMGN) | $54.60B | Healthcare |
| Merck & Co., Inc. (MRK) | $50.53B | Healthcare |
| Johnson & Johnson (JNJ) | $47.93B | Healthcare |
| Eli Lilly and Company (LLY) | $42.50B | Healthcare |
| AstraZeneca PLC (AZN) | $29.70B | Healthcare |
Frequently asked questions
What is Vertex Pharmaceuticals's total debt?
- Latest reported total debt for Vertex Pharmaceuticals (VRTX) is $3.88B (period ending December 31, 2025).
How has Vertex Pharmaceuticals total debt changed year-over-year?
- Vertex Pharmaceuticals (VRTX) total debt changed +121.9% year-over-year on the latest annual filing.
What is the long-term growth rate of Vertex Pharmaceuticals total debt?
- Vertex Pharmaceuticals (VRTX) total debt compound annual growth rate is +33.0% over the most recent 5 years available.
When did Vertex Pharmaceuticals total debt hit its highest annual value?
- Vertex Pharmaceuticals total debt reached its highest annual value of $3.88B in 2025.
What was Vertex Pharmaceuticals total debt in 2024?
- Vertex Pharmaceuticals (VRTX) total debt in 2024 was $1.75B.
What was Vertex Pharmaceuticals total debt in 2025?
- Vertex Pharmaceuticals (VRTX) total debt in 2025 was $3.88B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
VRTX Overview
Company profile, financial tools, and key metrics
VRTX Revenue Counter
Earns $381.74 every second. See per minute, hour, and day.
VRTX Earnings Counter
Earns $125.36 per second net profit. See per minute, hour, and day.
VRTX Economic Scale
Exceeds Somalia, Fed. Rep.'s GDP. Compare with world economies.
VRTX What If Invested
What if you had invested $1,000? See historical returns from any date.
VRTX How It Makes Money
Discover visual breakdown of $12.04B in revenue — where it comes from and where it goes.
VRTX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
VRTX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
VRTX Daily Price Character
Explosive · 48.3% historical win rate (green days). Streaks & record days.
VRTX Buybacks
1.75% TTM buyback yield. Shareholder yield & SBC comparison.
VRTX Stock Split History
1 split on record. Dates, ratios, and cumulative multiple.